BIS ProShares UltraShort Nasdaq Biotechnology

USD 17.58 0.14 0.802752
Icon

ProShares UltraShort Nasdaq Biotechnology (BIS) Stock Analysis and Price Targets

ETF | Trading--Inverse Equity | NSD
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 17.58

+0.14 (+0.80)%

USD 3.90M

2.50K

N/A

N/A

Icon

BIS

ProShares UltraShort Nasdaq Biotechnology (USD)
ETF | NSD
USD 17.58
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 3.90M

N/A

USD 17.58

ProShares UltraShort Nasdaq Biotechnology (BIS) Stock Forecast

N/A

Based on the ProShares UltraShort Nasdaq Biotechnology stock forecast from 0 analysts, the average analyst target price for ProShares UltraShort Nasdaq Biotechnology is not available over the next 12 months. ProShares UltraShort Nasdaq Biotechnology’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of ProShares UltraShort Nasdaq Biotechnology is Slightly Bullish , which is based on 7 positive signals and 4 negative signals. At the last closing, ProShares UltraShort Nasdaq Biotechnology’s stock price was USD 17.58. ProShares UltraShort Nasdaq Biotechnology’s stock price has changed by -0.17% over the past week, +3.78% over the past month and -16.52% over the last year.

No recent analyst target price found for ProShares UltraShort Nasdaq Biotechnology
No recent average analyst rating found for ProShares UltraShort Nasdaq Biotechnology

Company Overview ProShares UltraShort Nasdaq Biotechnology

The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified ...Read More

http://www.proshares.com

N/A

0

N/A

USD

USA

06/04/2010

NASDAQ Biotechnology TR USD

S&P 500 TR USD

0.95 %

Adjusted Closing Price for ProShares UltraShort Nasdaq Biotechnology (BIS)

Loading...

Unadjusted Closing Price for ProShares UltraShort Nasdaq Biotechnology (BIS)

Loading...

Share Trading Volume for ProShares UltraShort Nasdaq Biotechnology Shares

Loading...

Compare Performance of ProShares UltraShort Nasdaq Biotechnology Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for BIS

Top Sectors

N/A

Top Regions

N/A

Valuation Growth & Performance

  • 0

  • S&P 500 TR USD

  • N/A

  • 34.55

  • 0.00

  • -0.08

  • -1.68%

  • -5.33%

  • -22.84%

  • 0%

Stocks Similar To ProShares UltraShort Nasdaq Biotechnology (Sector: Trading--Inverse Equity )

Symbol Name Mer Price(Change) Market Cap
SQQQ
ProShares UltraPro Short QQQ 0.95 % +0.08 (+0.77%) USD3.06B

ETFs Containing BIS

Symbol Name BIS's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About ProShares UltraShort Nasdaq Biotechnology (BIS) Stock

Stock Target Advisor's fundamental analysis for ProShares UltraShort Nasdaq Biotechnology's stock is Slightly Bullish .

BIS stock's dividend yield is 1.79%. Our analysis grades BIS stock's dividend yield at F. This means that BIS stock's dividend yield is above 50% of the stocks in the Trading--Inverse Equity sector in the NSD exchange. Based on this BIS may be a average dividend stock for its sector.

Unfortunately we do not have enough data on BIS's stock to indicate what its average analyst target is.

BIS stock's Price/Earning ratio is 8.04. Our analysis grades BIS stock's Price / Earning ratio at A+. This means that BIS stock's Price/Earning ratio is above 0% of the stocks in the Trading--Inverse Equity sector in the NSD exchange. Based on this BIS may be undervalued for its sector.

The last closing price of BIS's stock was USD 17.58.

The most recent market capitalization for BIS is USD 3.90M.

Unfortunately we do not have enough analyst data on BIS's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains ProShares UltraShort Nasdaq Biotechnology's stock.

As per our most recent records ProShares UltraShort Nasdaq Biotechnology has 0 Employees.

Sorry we do not have any infomation available on ProShares UltraShort Nasdaq Biotechnology's address.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...